Oscar Health $OSCR price target raised to $49 from $39 at Barclays Barclays analyst Andrew Mok raised the firm's price target on Oscar Health to $49 from $39 and keeps an Overweight rating on the shares following the investor day. Oscar outlined a "credible path" to over $4 of earnings per share by 2029 and implied 2027 earnings over $3.00 versus the $1.92 Street estimate, the analyst tells investors in a research note. Barclays sees "significant growth ahead" for Oscar.

Oscar Isaac says Carey Mulligan is the best actor he’s ever worked with: “Nobody compares to her in my book, She’s incredibly funny, deep, and soulful. She’s both intuitive and also incredibly precise. It’s a real magic trick with her.”